---
title: "LDLR Promoter Hypermethylation Rarely Explains Mutation-Negative Familial Hypercholesterolemia"
id: "medrxiv-3-promoter-methylation-of-ldlr-is-not-a-common-cause-of-familial"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-3-promoter-methylation-of-ldlr-is-not-a-common-cause-of-familial"
content_type: "clinical_feed_article"
specialty: "Cardiology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.11.16.26368244v1?rss=1"
published_at: "2026-11-19T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# LDLR Promoter Hypermethylation Rarely Explains Mutation-Negative Familial Hypercholesterolemia
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-3-promoter-methylation-of-ldlr-is-not-a-common-cause-of-familial
- **Specialty:** [Cardiology](https://medichelpline.com/clinical-feed/cardiology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.11.16.26368244v1?rss=1)
- **Published At:** 2026-11-19T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The study screened 308 clinically confirmed, mutation-negative familial hypercholesterolemia (FH) patients for promoter hypermethylation of **LDLR** using peripheral blood DNA. - Investigators applied Combined Bisulfite Restriction Analysis (COBRA) to assess methylation at TaqI sites within a 332 bp region of the **LDLR** promoter; the source did not report additional assay parameters beyond this description. - No cases of promoter hypermethylation at the assayed locus were observed among the 308 patients, indicating absence of this specific epimutation in the cohort. - Statistical analysis provided an upper prevalence bound of 1.19% (95% Clopper–Pearson CI) for this epimutation in the screened population. - Authors noted that constitutional hypermethylation at this specific promoter locus is not a common cause of the FH phenotype in mutation-negative patients. - The manuscript states that other explanations for the diagnostic gap may include methylation at different loci, polygenic risk, structural variants, or non-canonical regulatory mutations; the study did not test these possibilities. - Ethical approvals and informed consent were obtained and documented; data are available on request from the authors. - Funding support was declared from the National Institute on Aging (AG075051); the authors declared no competing interests. - The report is a medRxiv preprint; the source did not provide replication cohorts, longitudinal follow-up, or functional assays of LDLR expression linked to methylation status. - Key unanswered questions remain: prevalence of methylation elsewhere in the gene or regulatory landscape, contribution of polygenic risk to mutation-negative FH, and the role of structural or regulatory variants not captured by the screening approach.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=9j0bHmfPMTE5mVhbIyKTD5uvNMJnz.DkKMVmAlTm6.k-1795158943.0464294-1.2.1.1-WjBAQO2PpXC8iZp1D4IHuhcuTDIycyPakE7ZghFHYhUbpf1DBBCwbCOYeKojdNmB) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.11.16.26368244v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Promoter methylation of _LDLR_ is not a common cause of familial hypercholesterolemia [ View ORCID Profile](http://orcid.org/0000-0003-3556-1492)Gabrielle Nicole Altman, Alejandro Marti-Trujillo, Luke B. Hesson, Damon A. Bell, Amanda J. Hooper, Andrew J. Sharp doi: https://doi.org/10.64898/2026.11.16.26368244 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Gabrielle Nicole Altman 1 Icahn School of Medicine at Mount Sinai; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Gabrielle%2BNicole%2BAltman%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Altman%20GN&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AGabrielle%2BNicole%2BAltman%2B) * [ORCID record for Gabrielle Nicole Altman](http://orcid.org/0000-0003-3556-1492 "Open in new tab") Alejandro Marti-Trujillo 1 Icahn School of Medicine at Mount Sinai; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Alejandro%2BMarti-Trujillo%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Marti-Trujillo%20A&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAlejandro%2BMarti-Trujillo%2B) Luke B. Hesson 2 Department of Genetics, Douglass Hanly Moir Pathology, 14 Giffnock Avenue, Macquarie Park, NSW 2113, Australia; School of Life Sciences, Faculty of Science, University of Technology Sydney, Ultimo, NSW 2007, Australia; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Luke%2BB.%2BHesson%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Hesson%20LB&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ALuke%2BB.%2BHesson%2B) Damon A. Bell 3 Department of Clinical Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital and Fiona Stanley Hospital Network, Perth, WA 6000, Australia; School of Medicine, University of Western Australia, Perth, WA 6009, Australia * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Damon%2BA.%2BBell%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Bell%20DA&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADamon%2BA.%2BBell%2B) Amanda J. Hooper 3 Department of Clinical Biochemistry, PathWest Laboratory Medicine WA, Royal Perth Hospital and Fiona Stanley Hospital Network, Perth, WA 6000, Australia; School of Medicine, University of Western Australia, Perth, WA 6009, Australia * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Amanda%2BJ.%2BHooper%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Hooper%20AJ&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAmanda%2BJ.%2BHooper%2B) Andrew J. Sharp 1 Icahn School of Medicine at Mount Sinai; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Andrew%2BJ.%2BSharp%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Sharp%20AJ&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAndrew%2BJ.%2BSharp%2B) * For correspondence: andrew.sharp@mssm.edu * [Abstract](https://www.medrxiv.org/content/10.64898/2026.11.16.26368244v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1349315/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.11.16.26368244v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1349315/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.11.16.26368244v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1349315/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.11.16.26368244v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1349315/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.11.16.26368244v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1349315/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract **Background/Objectives:** Familial hypercholesterolemia (FH) is a widely prevalent inherited disorder defined by chronically high LDL-C concentrations and a significantly increased risk of cardiovascular disease. While FH is primarily an autosomal dominant disease caused by pathogenic mutations in _LDLR_ , _APOB_ , or _PCSK9_ , approximately 20-60% of clinically diagnosed patients are mutation-negative. A previous survey of over 23,000 methylation profiles identified a differentially methylated region in the promoter of _LDLR_. This study aimed to investigate whether constitutional hypermethylation of the _LDLR_ promoter is a recurrent cause of FH in patients lacking identifiable pathogenic variants. **Methods:** We screened 308 mutation-negative clinically confirmed FH patients for promoter hypermethylation in _LDLR_. We used Combined Bisulfite Restriction Analysis (COBRA) with genomic DNA from peripheral blood samples. The assay assessed methylation at TaqI sites within a 332 bp region of the _LDLR_ promoter. **Results:** No instances of _LDLR_ promoter hypermethylation were detected among the 308 mutation-negative FH patients. Statistical analysis yielded an upper bound of 1.19% (95% Clopper-Pearson CI) for the prevalence of this specific epimutation in our cohort. **Conclusions:** Our results indicate that _LDLR_ promoter hypermethylation at this specific locus is not a common cause of the FH phenotype in mutation-negative patients. These findings imply that while methylation in this region may be rare or not significantly contribute to the disease phenotype, the diagnostic gap in FH may be explained by other factors, such as methylation in other regions, polygenic risk, structural variants, or non-canonical regulatory mutations. ### Competing Interest Statement The authors have declared no competing interest. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of the Icahn School of Medicine at Mount Sinai (STUDY-22-01301; October 24th, 2022). Informed consent was obtained from all subjects involved in the study. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability All data produced in the present study are available upon reasonable request to the authors. ## Funder Information Declared National Institute on Aging, https://ror.org/049v75w11, AG075051 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.11.16.26368244v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.11.17.26368266v1 "Automated Gland MRI Radiomics for Predicting Time to Pathologic Progression during Prostate Cancer Active Surveillance") Posted November 19, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.11.16.26368244v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/11/19/2026.11.16.26368244.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.11.16.26368244v1#p-5) [ Data/Code](https://www.medrxiv.org/content/early/2026/11/19/2026.11.16.26368244.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Promoter methylation of _LDLR_ is not a common cause of familial hypercholesterolemia Gabrielle Nicole Altman, Alejandro Marti-Trujillo, Luke B. Hesson, Damon A. Bell, Amanda J. Hooper, Andrew J. Sharp medRxiv 2026.11.16.26368244; doi: https://doi.org/10.64898/2026.11.16.26368244 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.16.26368244v1%26text%3DPromoter%2520methylation%2520of%2520LDLR%2520is%2520not%2520a%2520common%2520cause%2520of%2520familial%2520hypercholesterolemia "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.16.26368244v1%26t%3DPromoter%2520methylation%2520of%2520LDLR%2520is%2520not%2520a%2520common%2520cause%2520of%2520familial%2520hypercholesterolemia "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.16.26368244v1%26title%3DPromoter%2520methylation%2520of%2520LDLR%2520is%2520not%2520a%2520common%2520cause%2520of%2520familial%2520hypercholesterolemia%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.11.16.26368244v1%26title%3DPromoter%2520methylation%2520of%2520LDLR%2520is%2520not%2520a%2520common%2520cause%2520of%2520familial%2520hypercholesterolemia "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.11.16.26368244) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.11.16.26368244v1&count=horizontal&via=&text=Promoter%20methylation%20of%20LDLR%20is%20not%20a%20common%20cause%20of%20familial%20hypercholesterolemia&counturl=www.medrxiv.org/content/10.64898/2026.11.16.26368244v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (642) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (927) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (355) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (5055) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (496) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (432) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (681) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1703) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (16339) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (37) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1248) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (7328) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (759) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1101) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (5346) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1480) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1847) * [Hematology](https://www.medrxiv.org/collection/hematology) (604) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1389) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16534) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1209) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (702) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (157) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (757) * [Neurology](https://www.medrxiv.org/collection/neurology) (7659) * [Nursing](https://www.medrxiv.org/collection/nursing) (380) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1142) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1306) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (1045) * [Oncology](https://www.medrxiv.org/collection/oncology) (3765) * [Ophthalmology](https://www.medrxiv.org/collection/ophthalmology) (1105) * [Orthopedics](https://www.medrxiv.org/collection/orthopedics) (413) * [Otolaryngology](https://www.medrxiv.org/collection/otolaryngology) (473) * [Pain Medicine](https://www.medrxiv.org/collection/pain-medicine) (506) * [Palliative Medicine](https://www.medrxiv.org/collection/palliative-medicine) (144) * [Pathology](https://www.medrxiv.org/collection/pathology) (726) * [Pediatrics](https://www.medrxiv.org/collection/pediatrics) (1877) * [Pharmacology and Therapeutics](https://www.medrxiv.org/collection/pharmacology-and-therapeutics) (758) * [Primary Care Research](https://www.medrxiv.org/collection/primary-care-research) (791) * [Psychiatry and Clinical Psychology](https://www.medrxiv.org/collection/psychiatry-and-clinical-psychology) (6184) * [Public and Global Health](https://www.medrxiv.org/collection/public-and-global-health) (10047) * [Radiology and Imaging](https://www.medrxiv.org/collection/radiology-and-imaging) (2559) * [Rehabilitation Medicine and Physical Therapy](https://www.medrxiv.org/collection/rehabilitation-medicine-and-physical-therapy) (1538) * [Respiratory Medicine](https://www.medrxiv.org/collection/respiratory-medicine) (1280) * [Rheumatology](https://www.medrxiv.org/collection/rheumatology) (666) * [Sexual and Reproductive Health](https://www.medrxiv.org/collection/sexual-and-reproductive-health) (813) * [Sports Medicine](https://www.medrxiv.org/collection/sports-medicine) (601) * [Surgery](https://www.medrxiv.org/collection/surgery) (809) * [Toxicology](https://www.medrxiv.org/collection/toxicology) (109) * [Transplantation](https://www.medrxiv.org/collection/transplantation) (321) * [Urology](https://www.medrxiv.org/collection/urology) (309) Evaluation/discussion of this paper x Comments 0TRiP 0Community 0Automated 0Blogs/Media 0Video 0 Comments medRxiv aims to provide a venue for anyone to comment on a medRxiv preprint. Comments are moderated for offensive or irrelevant content (this can take ~24 h). Please avoid duplicate submissions. The content of a comment is not endorsed by medRxiv. medRxiv is now using a new commenting interface powered by Hypothes.is. All comments previously submitted via the legacy platform (Disqus) have been transferred to the new platform using the medRxiv_admin account. Please read our [commenting guide](https://connect.biorxiv.org/news/2022/03/21/commenting_on_preprints) for more information. Share this comments tab (click to copy link)Copied! TRiP medRxiv partners with journals and review services to enable posting of peer reviews and editorial decisions related to p
## Related Clinical Research

- [Watchman cardiac implant: clinicians raise questions as Boston Scientific intensifies sales push](https://medichelpline.com/clinical-feed/stat-news-1-stat-doctors-have-questions-about-the-watchman-boston-scientific-has-a-sales.md)
- [Cardiovascular drug research after high-profile trial failures and safety alarms](https://medichelpline.com/clinical-feed/stat-news-6-the-future-of-heart-drug-research-in-the-wake-of-study-setbacks.md)
- [GLP-1 RAs on Top of Statins Linked to Lower Mortality, MI, and Stroke in ASCVD with Obesity](https://medichelpline.com/clinical-feed/medrxiv-0-glp-1-receptor-agonists-added-to-statin-therapy-and-cardiovascular-outcomes-in.md)
- [Simulated ICU Trajectories After Stroke: Temporal Validation Using MIMIC‑IV](https://medichelpline.com/clinical-feed/medrxiv-1-simulation-and-temporal-validation-of-icu-trajectories-after-stroke-patient.md)
- [Racial and Ethnic Inequities in Diabetes Care: Diagnostic, Treatment, and Outcome Gaps](https://medichelpline.com/clinical-feed/pubmed-42460782.md) (DOI: 10.1210/clinem/dgag277)

## Navigation
- [← Back to Cardiology Feed](https://medichelpline.com/clinical-feed/cardiology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.